Predictive Oncology (POAI) 10-K 31 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001446159
Entity Registrant Name	Predictive Oncology Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-36790
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	2915 Commers Drive, Suite 900
Entity Address, City or Town	Eagan
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55121
City Area Code	651
Local Phone Number	389-4800
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 85,590,000
Entity Common Stock, Shares Outstanding		65,911,001
Auditor Name	Baker Tilly US, LLP
Auditor Location	Minneapolis, Minnesota
Auditor Firm ID	23

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 28,202,615	$ 678,332
Accounts Receivable	354,196	256,878
Inventories	387,684	289,535
Prepaid Expense and Other Assets	513,778	289,490
Total Current Assets	29,458,273	1,514,235
Fixed Assets, net	2,511,571	3,822,700
Intangibles, net	3,962,118	3,398,101
Lease Right-of-Use Assets	814,454	1,395,351
Other Long-Term Assets	167,065	116,257
Goodwill	6,857,790	2,813,792
Total Assets	43,771,271	13,060,436
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	1,021,774	1,372,070
Notes Payable – Net of Discounts of $0 and $244,830	0	4,431,925
Accrued Expenses and other liabilities	1,262,641	2,588,047
Derivative Liability	129,480	294,382
Deferred Revenue	186,951	53,028
Lease Liability – Net of Long-Term Portion	639,662	597,469
Total Current Liabilities	3,240,508	9,336,921
Other Long Term Liabilities	25,415	235,705
Lease Liability, long-term portion	239,664	845,129
Total Liabilities	3,505,587	10,417,755
Stockholders’ Equity:
Common Stock, $.01 par value, 200,000,000 and 100,000,000 authorized, 65,614,597 and 19,804,787 outstanding	656,146	198,048
Additional Paid-in Capital	167,649,028	110,826,949
Accumulated Deficit	(128,040,282)	(108,383,108)
Total Stockholders' Equity	40,265,684	2,642,681
Total Liabilities and Stockholders' Equity	43,771,271	13,060,436
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 authorized, 79,246 and 79,246 shares outstanding	$ 792	$ 792

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Discount of note payable	$ 0	$ 244,830
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	100,000,000
Common stock, shares outstanding (in shares)	65,614,597	19,804,787
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)	79,246	79,246

Consolidated Statements of Net

Consolidated Statements of Net Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 1,420,680	$ 1,252,272
Cost of goods sold	487,024	447,192
Gross profit	933,656	805,080
General and administrative expense	10,932,125	10,351,973
Operations expense	2,698,565	2,351,709
Sales and marketing expense	774,530	584,937
Loss on goodwill impairment	2,813,792	12,876,498
Loss on impairment intangibles	2,893,548	0
Loss on impairment of software acquired	1,249,727	0
Total operating loss	(20,428,631)	(25,360,037)
Other income	184,528	843,440
Other expense	(239,631)	(2,427,026)
Loss on early extinguishment of debt	0	(1,996,681)
Gain on derivative instruments	164,902	1,765,907
Gain on notes receivables associated with asset purchase	0	1,290,000
Net loss before income tax benefit	(20,318,832)	(25,884,397)
Income tax benefit	(661,658)	0
Net loss	(19,657,174)	(25,884,397)
Deemed dividend	0	554,287
Net loss attributable to common shareholders	$ (19,657,174)	$ (26,438,684)
Loss per common share - basic and diluted (in dollars per share)	$ (0.36)	$ (2.21)
Weighted average shares used in computation - basic and diluted (in shares)	54,876,044	11,950,154

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	June 2020 Warrant [Member]Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	June 2020 Warrant [Member]Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	June 2020 Warrant [Member]Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	June 2020 Warrant [Member]Common Stock [Member]	June 2020 Warrant [Member]Additional Paid-in Capital [Member]	June 2020 Warrant [Member]Retained Earnings [Member]	June 2020 Warrant [Member]	Warrants Issued Pursuant to 2020 Convertible Debt [Member]Additional Paid-in Capital [Member]	Warrants Issued Pursuant to 2020 Convertible Debt [Member]	Warrants Issued Pursuant to 2020 Convertible Debt 2 [Member]Additional Paid-in Capital [Member]	Warrants Issued Pursuant to 2020 Convertible Debt 2 [Member]	Prefunded Warrants [Member]Common Stock [Member]	Prefunded Warrants [Member]Additional Paid-in Capital [Member]	Prefunded Warrants [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Registered Direct Offerings [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]June 2021 Offering [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]Series E Preferred Stock Conversions [Member]	Preferred Stock [Member]Series E Convertible Preferred Stock [Member]	Common Stock [Member]Registered Direct Offerings [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]June 2021 Offering [Member]	Common Stock [Member]May 2020 Offering [Member]	Common Stock [Member]Bridge Notes [Member]	Common Stock [Member]Series E Preferred Stock Conversions [Member]	Common Stock [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Registered Direct Offerings [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]June 2021 Offering [Member]	Additional Paid-in Capital [Member]May 2020 Offering [Member]	Additional Paid-in Capital [Member]Bridge Notes [Member]	Additional Paid-in Capital [Member]Series E Preferred Stock Conversions [Member]	Additional Paid-in Capital [Member]Conversion of Series D Preferred Stock to Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Registered Direct Offerings [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]June 2021 Offering [Member]	Retained Earnings [Member]	Registered Direct Offerings [Member]	Private Placement [Member]	June 2021 Offering [Member]	May 2020 Offering [Member]	Bridge Notes [Member]	Total
Balance (in shares) at Dec. 31, 2019																		79,246		3,500,000		258								4,056,652
Balance at Dec. 31, 2019																		$ 792		$ 35,000		$ 3								$ 40,567								$ 93,653,667				$ (82,498,711)						$ 11,231,318
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)																														1,583,481
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement																														$ 15,835								2,307,043										2,322,878
Inducement shares issued pursuant to promissory note extension (in shares)																														30,000
Inducement shares issued pursuant to promissory note extension																														$ 300								40,950										41,250
Issuance of shares and prefunded warrants pursuant to March 2020 private placement (in shares)																														260,000
Issuance of shares and prefunded warrants pursuant to March 2020 private placement																														$ 2,600								455,223										457,823
Inducement shares issued pursuant to 2020 convertible debt and warrants (in shares)																														46,875
Inducement shares issued pursuant to 2020 convertible debt and warrants																														$ 468								119,532										120,000
Warrants issued pursuant to 2020 convertible debt								$ 116,951	$ 116,951	$ 62,373	$ 62,373
Shares issued pursuant to conversions (in shares)																			(3,500,000)		(258)						170,000	1,398,607	350,004	2,212,359
Shares issued pursuant to conversions																			$ (35,000)		$ (3)						$ 1,700	$ 13,986	$ 3,500	$ 22,124					$ 265,628	$ (13,983)	$ 31,500	1,006,230									$ 267,328	1,028,354
Issuance of shares from prefunded warrant exercises (in shares)				1,274,826								1,390,166																		122,000
Issuance of shares from prefunded warrant exercises				$ 12,748	$ 1,682,237		$ 1,694,985					$ 13,902	$ (13,149)	$ 753																$ 1,220								190,930										192,150
Shares issued (in shares)																										1,396,826
Issuance of shares																										$ 13,968								$ 591,949												$ 605,917
Shares issued in connection with asset purchase agreement (in shares)																														1,079,719
Shares issued in connection with asset purchase agreement																														$ 10,797								1,661,970										1,672,767
Repricing and Reclassification of warrants issued pursuant to convertible debt					$ 803,455		$ 803,455																															1,865,953										1,865,953
Shares issued pursuant to Equity Line (in shares)																														4,231,073
Shares issued pursuant to Equity Line																														$ 42,311								4,849,037										4,891,348
Share issuance to consultant and other (in shares)																														202,199
Share issuance to consultant and other																														$ 2,022								428,184										430,206
Vesting expense and option repricing																																						721,269										721,269
Net loss																																										(25,884,397)						(25,884,397)
Balance (in shares) at Dec. 31, 2020																		79,246		0		0								19,804,787
Balance at Dec. 31, 2020																		$ 792		$ 0		$ 0								$ 198,048								110,826,949				(108,383,108)						2,642,681
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)																														400,000
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement																														$ 4,000								(4,000)										0
Shares issued pursuant to conversions (in shares)																														1,107,544
Shares issued pursuant to conversions																														$ 11,075								502,936										514,011
Issuance of shares from prefunded warrant exercises (in shares)																														5,269,059
Issuance of shares from prefunded warrant exercises																														$ 52,702								4,461,169										4,513,871
Shares issued (in shares)																							13,488,098	9,043,766	15,520,911
Issuance of shares																							$ 134,881	$ 90,438	$ 155,209						$ 14,877,611	$ 15,974,301	$ 19,291,087										$ 15,012,492	$ 16,064,739	$ 19,446,296
Shares issued pursuant to Equity Line (in shares)																														647,504
Shares issued pursuant to Equity Line																														$ 6,475								669,115										675,590
Share issuance to consultant and other (in shares)																														174,954
Net loss																														$ 0								0				(19,657,174)						(19,657,174)
Balance (in shares) at Dec. 31, 2021																		79,246												65,614,597
Balance at Dec. 31, 2021																		$ 792												$ 656,146								167,649,028				(128,040,282)						40,265,684
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)																														100,401
Shares issued pursuant to agreement with former CEO related to accrued interest																														$ 1,004								142,569										143,573
Share issuance to consultant and other																														$ 1,750								203,443										205,193
Vesting expense and option repricing (in shares)																														57,573
Vesting expense and option repricing																														$ 564								$ 703,848										$ 704,412

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flow from operating activities:
Net loss	$ (19,657,174)	$ (25,884,397)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,340,301	1,024,848
Vesting expense	715,938	721,269
Equity instruments issued for management, consulting, and other	205,193	450,901
Amortization of debt discount	244,830	1,246,541
Gain on valuation of equity-linked instruments	(164,902)	(1,765,907)
Income tax benefit	(661,658)	0
Gain on note receivable associated with asset purchase agreement	0	(1,290,000)
Gain on extinguishment of PPP loan	0	(541,867)
Debt extinguishment costs	0	1,996,681
Loss on goodwill impairment	2,813,792	12,876,498
Loss on intangible impairment	2,893,548	0
Loss on impairment of software acquired	1,249,727	0
Loss on fixed asset disposal	5,858	120,577
Changes in assets and liabilities:
Accounts receivable	(20,769)	69,913
Inventories	(98,149)	(94,715)
Prepaid expense and other assets	(194,363)	(245,526)
Accounts payable	(350,296)	(1,688,572)
Accrued expenses	(499,563)	700,966
Deferred revenue	54,548	12,644
Other liabilities	85,790	(32,414)
Net cash used in operating activities:	(12,208,929)	(12,257,732)
Cash flow from investing activities:
Acquisition of zPREDICTA, net of cash acquired	(9,590,214)	0
Purchase of fixed assets	(910,429)	(298,379)
Proceeds from sale of fixed assets	0	193,321
Acquisition of intangibles	(51,893)	(62,398)
Loan activities	(55,000)	0
Net cash used in investing activities	(10,607,536)	(167,456)
Cash flow from financing activities:
Proceeds from issuance of common stock, net	50,523,527	0
Proceeds from exercise of warrants into common stock	4,513,871	1,935,855
Proceeds from debt issuance	0	2,761,867
Repayment of debt	(4,162,744)	(1,472,389)
Payment penalties	(1,073,470)	(247,327)
Proceeds from issuance of stock pursuant to equity line	675,590	4,891,348
Issuance of common stock, prefunded warrants, warrants and exchange of warrants, net	0	5,057,919
Repurchase of common stock upon vesting of restricted stock units	(11,526)	0
Other liabilities	(124,500)	25,416
Net cash provided by financing activities	50,340,748	12,952,689
Net increase in cash and cash equivalents	27,524,283	527,501
Cash and cash equivalents at beginning of year	678,332	150,831
Cash and cash equivalents end of year	28,202,615	678,332
Non-cash transactions
Debt Conversion, Converted Instrument, Amount	0	267,328
Warrants issued pursuant to debt issuance	$ 0	$ 179,324
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)	0	2,322,878
Shares issued pursuant to former CEO per agreement related to accrued interest	$ 143,573	$ 0
Fixed assets acquired for notes receivable and common stock	0	2,962,767
Increase to operating lease right of use asset and lease liability due to new and modified leases	77,128	1,417,077
Put and conversion derivative from debt issuance and modification	0	636,563
Inducement shares issued pursuant to convertible debt	514,011	0
Fixed assets acquired for financing arrangements	0	113,192
Cash paid during the period for:
Interest paid on debt	690,508	145,831
Conversion of Series D Preferred Stock to Common Stock [Member]
Non-cash transactions
Preferred stock conversions	0	35,000
Conversion of Series E Preferred Stock [Member]
Non-cash transactions
Preferred stock conversions	0	13,983
Stock Issued for Convertible Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	0	1,028,354
Stock Issued for Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	$ 0	$ 140,555

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company” or “Predictive” or “we”) filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name to Predictive Oncology Inc. on June 10, 2019, June 13, 2019. The Company operates in four The Company had cash and cash equivalents of $28,202,615 as of December 31, 2021. December 31, 2021, twelve may Coronavirus Outbreak The current COVID- 19 19 19 may 19 may 19 10 Recently Adopted Accounting Standards The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023. Accounting Policies and Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates. Reclassifications Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. The reclassifications had no Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts. Amounts recorded in accounts receivable on the consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not December 31, 2021 2020. Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives 3 Note 10 Goodwill and Intangibles The acquisition of zPREDICTA was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the acquisition date. The majority of the inputs used in the discounted cash flow model, the relief-from-royalty method under the income approach, the distributor method under the income approach and the multi-period excess earnings method under the income approach, each are unobservable and thus are considered to be Level 3 Note 2 zPREDICTA Acquisition Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company prepared an undiscounted cash flow as of December 31, 2021 360. not December 31, 2021. December 31, 2021 no December 31, 2021. 10 The Company also prepared an undiscounted cash flow as of December 31, 2020 no December 31, 2020. Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, 3 1 3 Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing C one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2021 2020, The Company’s deferred revenues related primarily to our zPREDICTA contract research revenue and maintenance plans of our Skyline Medical operating segment. As of December 31, 2021 2020, Practical Expedients The Company has elected the practical expedient not Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the Year Ended December 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.66% 0.13% - 1.78% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% - 87% Risk-free interest rate 0.42% - 0.69% 0.135% - 0.79% Expected life (years) 5/ 5.5 5/ 5.5 Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $315,850 and $372,710 for the years ended 2021 2020, Other Expense Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable. Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2001 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one December 31, 2021. not Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not The Company has evaluated all of its activities and concluded that no Note 16 Subsequent Events

Note 2 - zPredicta Acquisition

Note 2 - zPredicta Acquisition	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 2 zPREDICTA ACQUISITION On November 24, 2021, November 24, 2021, As consideration for the acquisition, the stockholders and certain holders of interests in zPREDICTA as of immediately prior to the transaction collectively received consideration of approximately $10.0 million in cash. The Agreement contains customary and negotiated representations, warranties, and indemnity provisions. The acquisition costs of $895,297 related to the acquisition are presented in legal, accounting and consulting expenses within general and administrative expenses in the accompanying consolidated statements of net loss. The following table summarizes the acquisition date fair values of assets acquired and liabilities assumed, and the consideration transferred: Cash consideration $ 10,015,941 Assets acquired: Cash 425,727 Accounts receivable 76,549 Prepaid expenses 25,733 Intangible assets 3,780,000 Liabilities assumed: Accrued expenses (408,825 ) Deferred tax liability (661,658 ) Deferred revenue (79,375 ) Goodwill $ 6,857,790 The purchase price allocation has been derived from estimates. The Company’s judgements used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed can materially affect the consolidated operations of the consolidated Company. The total purchase price has been allocation to identifiable assets acquired and liabilities assumed based upon valuation studies and procedures performed to date. The fair value and useful life for the intangible assets are (a) tradename $80,000 b) developed technology $3,500,000 and c) customer relationships $200,000 with useful lives of 4 years, 10 years and 10 years, respectively all using a straight-line method. The Company acquired zPREDICTA through a non-taxable reverse triangular merger combination. As part of purchase accounting there was $3,780,000 in fair value assigned to purchased intangibles which the Company established a related deferred tax liability as a result of the stock merger combination that offset the acquired deferred assets including NOL’s and other temporary timing differences. Identifiable Intangible Assets The Company acquired intangible assets related to trademarks for the acquired zPREDICTA trade name with an estimated fair market value of $80,000. 4 December 31, 2021. The Company acquired intangible assets with a useful life of 10 $200,000 The Company acquired intangible assets with a useful life of 10 $3,500,000 3D Goodwill Goodwill of $6,857,790 was recognized in the zPREDICTA acquisition and represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and represents the future economic benefits and synergies arising from the transaction. None Note 10 Goodwill and Intangibles Financial Results The financial results of zPREDICTA since the acquisition date have been included in the Company’s accompanying consolidated statements of net loss. Pro Forma The following pro forma information presents the combined results of operations of the Company and zPREDICTA as if the acquisition of zPREDICTA had been completed on January 1, 2020, 2021 2020 Unaudited Unaudited Revenue $ 2,429,786 $ 1,815,560 Net loss attributable to common shareholders $ (18,878,432 ) $ (26,946,564 ) The primary adjustments include the inclusion of the revalued amortization for zPREDICTA intangible assets. The unaudited pro forma results do not may not There are certain portions of purchase accounting, specifically Section 382 Tax Loss Carryforwards not may

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 3 INVENTORIES Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first December 31, 2021 December 31, 2020 Finished goods $ 193,287 $ 95,898 Raw materials 183,410 151,366 Work-In-Process 10,987 42,271 Total $ 387,684 $ 289,535

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 STOCKHOLDERS EQUITY, STOCK OPTIONS AND WARRANTS Authorized Shares At the special meeting on August 17, 2021, August 17, 2021. 2021 In January February 2021, five first four one two four one two June 2021, August 17, 2021, three five one five three June 2021 five one These 2021 Offering Closing Date Shares Sale Price per Share* Investor Warrants Exercise Price per Share investor Warrants Placement Agent Warrants Exercise Price per Share Placement Agent Warrants Gross Proceeds of Offering Net Proceeds of Offering January 12, 2021 (registered direct) 3,650,840 $ 0.842 1,825,420 $ 0.80 273,813 $ 1.0525 $ 3,074,007 $ 2,731,767 January 21, 2021 (registered direct) 2,200,000 $ 1.00 1,100,000 $ 1.00 165,000 $ 1.25 $ 2,200,000 $ 1,932,050 January 26, 2021 (registered direct) 3,414,970 $ 1.20 1,707,485 $ 1.20 256,123 $ 1.50 $ 4,097,964 $ 3,668,687 February 16, 2021 (registered direct) 4,222,288 $ 1.75 2,111,144 $ 2.00 316,672 $ 2.1875 $ 7,389,004 $ 6,679,989 February 23, 2021 (private placement) 9,043,766 $ 1.95 4,521,883 $ 2.00 678,282 $ 2.4375 $ 17,635,344 $ 16,064,739 June 16, 2021 (registered direct) 15,520,911 $ 1.375 15,520,911 $ 1.25 1,164,068 $ 1.71875 $ 21,341,252 $ 19,446,296 Total 38,057,775 26,786,843 2,853,958 $ 55,737,571 $ 50,523,528 * one one one June 16, 2021 2021 During the year ended December 31, 2021, Equity Line On October 24, 2019, three three may December 31, 2020, December 31, 2021, December 31, 2021, Series D Preferred Stock In April 2019, 10:1 1 50% 2 one April 4, 2020, Series E Convertible Preferred Stock In June September 2019, six June 13, 2019. 12 December 13, 2019. During the first 2020, May 2020, June 13, 2020 June 13, 2020 June 12, 2020. March 2020 On March 18, 2020, five one two September 23, 2020. In addition, and in lieu of common shares, the investors also purchased prefunded warrants to purchase 1,390,166 shares of common stock at a purchase price of $2.12 per prefunded warrant, which represents the per share offering price, minus the $0.0001 per share exercise price of each such prefunded warrant. As a result of the prefunded warrants exercise price being of a nominal amount, these warrants were included as outstanding shares within our earnings per share calculation during the period from purchase through to exercise during the second 2020. The sale of the offering shares, prefunded warrants and A and B warrants resulted in gross proceeds of $3,498,612 and net proceeds of $3,127,818 after deducting the placement agent fees and estimated offering expenses payable by the Company. The Company agreed to use the net proceeds from the offering for general corporate purposes. The offering closed on March 18, 2020, Effective September 23, 2020, September, Note 7 Derivatives September 23, 2020. Dr. Schwartz Note Exchange Effective as of April 21, 2020, January 31, 2020 See Note 5 Notes Payable. May 2020 During May 2020, five one May 8, 2020. Acquisition from Soluble Therapeutics and BioDtech On May 27, 2020, two may six nine May 26, 2021. may six June 2020 During June 2020, May 2020 five one Effective on September 23, 2020, Acquisition of Quantitative Medicine On July 1, 2020, six one Warrants Issued in Connection with Helomics Acquisition September 14, 2020, April 4, 2019. September 2020, September 11, 2020, one ten 1:10 October 29, 2019). April 4, 2019 April 4, 2024. See Note 8 Loss per Share. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options, stock appreciation rights, stock awards, restricted stock, restricted stock units and performance awards to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three ten At the special meeting on August 17, 2021, 2012 Options and Warrants ASC 718, Compensation Stock Compensation, ( ASC 718 ) 718 The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. See Note 1 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.55 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 1.99 Issued 147,230 1.06 29,640,801 1.44 Forfeited (92,593 ) 8.64 - - Expired - - (25,233 ) 10.00 Exercised (5,313 ) 0.74 (5,269,059 ) 0.86 Outstanding at December 31, 2021 1,062,871 $ 4.83 31,699,885 $ 1.66 At December 31, 2021, December 31, 2020, December 31, 2020. 2021 2020 The following summarizes the status of options and warrants outstanding at December 31, 2021: Range of Exercise Prices Shares Weighted Average Remaining Life Options: 0.72 – 1.10 335,876 9.31 $1.15 – 1.64 356,673 8.36 $2.610 – 8.41 214,937 8.15 $10.10 – 5,962.50 155,385 5.99 Total 1,062,871 Warrants: $0.80-1.72 21,468,599 3.31 $1.80 – 2.18 8,451,287 4.50 $2.25 – 10.00 1,555,778 3.37 $10.71 – 22.50 224,221 2.94 Total 31,699,885 Stock options and warrants expire on various dates from August 2022 November 2031. Stock Options and Warrants Granted by the Company The following table is the listing of outstanding stock options and warrants as of December 31, 2021 Stock Options: Year Shares Price 2012 114 $1.54 – $1,500.00 2013 146 1.54 – 5,962.50 2014 84 1.54 – 3,468.75 2015 394 1.54 – 862.50 2016 9,174 1.54 – 42.50 2017 214,555 1.54 – 21.00 2018 78,325 1.54 – 13.50 2019 314,963 1.54 – 7.50 2020 303,199 0.73 – 3.48 2021 141,917 0.72 – 1.47 Total 1,062,871 $0.72 – $5,962.50 Warrants: Year Shares Price 2017 108,435 $10.71 – $22.50 2018 196,946 8.36 – 13.125 2019 1,690,286 0.845 – 11.80 2020 2,010,144 0.845 – 2.992 2021 27,694,074 0.80 – 2.992 Total 31,699,885 $0.80 – $22.50

Note 5 - Notes Receivable

Note 5 - Notes Receivable	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 NOTES RECEIVABLE The Company had a secured promissory note receivable from CytoBioscience for $1,112,524 ( “2017 February 28, 2020. 2019, first April 2019. not first 2019. 2019, 2019, On May 27, 2020, two may $1,290,000 2017

Note 6 - Notes Payable

Note 6 - Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 6 NOTES PAYABLE The balances of notes payable were as follows: Due Date December 31, 2021 December 31, 2020 2018 Investor loan March 31, 2021 $ - $ 1,721,776 Promissory note 2019 March 27, 2021 - 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - 244,830 Total Notes Payable, net $ - $ 4,431,925 Secured Notes and Repayment in Full In September 2018, two “2018 2018 2018 February 2019, 2018 2018 September 2019, 2018 one March 19, 2020, L2 “L2” June 28, 2020. L2 July 15, 2020 July 2020 September 30, 2020. September 30, 2020, L2 March 31, 2021. Each investor received the right to convert all or any part of its portion of the 2018 December 31, 2020, L2 During September 2019, “2019 L2, sixth fifth 2019 March 19, 2020, 2019 March 2020 June 27, 2020. 2019 10% 470, Debt first 2020, July 15, 2020 September 30, 2020. September 30, 2020 10% 470, Debt third 2020, 2019 September 30, 2020. September 30, 2020, 2019 March 31,2021. March 31, 2021 10% 470, Debt third 2020, March 31, 2021. $1.00 70% twenty 20 fourth 2020, 2019 December 31, 2020 not December 31, 2020. December 31, 2020, On February 5, 2020, “2020 third February 5, 2020, March 5, 2020, April 5, 2020, 2020 September 30, 2020 70% twenty 20 July 15, 2020, September 30, 2020. September 30, 2020 10% 470, Debt third 2020, September 30, 2020. September 30, 2020, 2020 March 31, 2021. March 31, 2021 10% 470, Debt third 2020, March 31, 2021. second third sixth first fourth 2020, December 31, 2020 not December 31, 2020. December 31, 2020, On March 1, 2021, February 23, 2021, “2021 2018 2019 2020 Dr. Schwartz Notes In November 2018, December 31, 2018, one November 30, 2018 July 15, 2019, two February 1, 2019 first October 2019, not During January 2020, two September 30, 2020 no December 31, 2019. Effective as of April 21, 2020, January 31, 2020 twelve September 30, 2020. April 21, 2020 April 21, 2020. 1 not three 2 not six 2021, 2020 February 24, 2021, Short Term Borrowings The Company entered into short-term borrowings with an investor. The maturity date of the notes is six December 31, 2020, December 31, 2020. December 31, 2020. April 2020 On April 20, 2020, 2 1% 6 60 Pursuant to the terms of the PPP, the promissory note, or a portion thereof, may fourth 2020.

Note 7 - Derivatives

Note 7 - Derivatives	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 7 The Company concluded the September 2018 December 31, 2020, December 31, 2020. zero December 31, 2020. The Company concluded the Promissory Note 2020 815, Derivatives and Hedging two second third December 31, 2020, March 1, 2021, zero December 31, 2021. December 31, 2020, The Company concluded the A, B and agent warrants issued in connection with the March 2020 third 2020, Note 6 no December 31, 2020. December 31, 2021, December 31, 2021. December 31, 2020, December 31, 2020. The Company concluded the warrants and agent warrants issued in connection with the May 2020 December 31, 2020. June 2020, December 31, 2021 December 31, 2020, December 31, 2021 December 31, 2020. In connection with the June 2020 June 2020 December 31, 2020, June no December 31, 2020. December 31, 2021 December 31, 2020. December 31, 2021 December 31, 2020, On September 30, 2020, 2019 2019 815, Derivatives and Hedging March 1, 2021, zero December 31, 2021. December 31, 2020. December 31, 2020, The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above. Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Reclassification of Warrant liabilities to Equity (2,669,408 ) Derivative instrument related to September 30 debt amendments 495,100 Gain recognized to revalue derivative instrument at fair value (1,765,906 ) Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (164,902 ) Derivative liability balance at December 31, 2021 $ 129,480

Note 8 - Loss Per Share

Note 8 - Loss Per Share	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended December 31, 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (19,657,174 ) $ (26,438,684 ) Denominator: Weighted average common shares outstanding-basic 54,876,044 11,950,154 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 54,876,044 11,950,154 Loss per common share-basic and diluted $ (0.36 ) $ (2.21 ) ( 1 Year Ended December 31, 2021 2020 Options 1,062,871 1,013,547 Warrants 31,699,885 7,353,376 Convertible debt - 1,107,544 Preferred stock: Series B 79,246 79,246

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9 INCOME TAXES The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company recognized an income tax benefit of $661,658 in our consolidated statement of net loss related to the release of valuation allowance as a result of the zPREDICTA business combination. However, due to the cumulative operating losses, the Company determined that a 100% valuation allowance for the net deferred tax assets at December 31st Actual income tax benefit differs from statutory federal income tax benefit as follows: Year Ended December 31, 2021 2020 Statutory federal income tax benefit $ 4,266,955 $ 5,434,463 State tax benefit, net of federal taxes 793,282 578,746 Foreign tax benefit - 62,146 Foreign operations tax rate differential - (44,120 ) State rate adjustment 5,153 65,112 Nondeductible/nontaxable items (260,768 ) (268,968 ) Goodwill impairment (605,420 ) (2,762,014 ) NOL adjustments (612,588 ) (1,141,662 ) Other 150,083 (461,020 ) Valuation allowance increase (3,075,039 ) (1,462,683 ) Total income tax benefit $ 661,658 $ - Deferred taxes consist of the following: December 31, 2021 December 31, 2020 Deferred tax assets: Noncurrent: Inventory $ - $ 7,196 Compensation accruals 58,829 63,846 Accruals and reserves 50,537 162,628 Deferred revenue 26,198 11,641 Charitable contribution carryover 1,095 4,331 Derivatives 27,859 63,145 Intangibles 700,876 295,941 Right of use asset 18,543 13,861 NSQO compensation 1,602,429 1,738,217 NOL and credits 82,814,111 80,038,356 Total deferred tax assets 85,300,477 82,400,860 Deferred tax liabilities: Noncurrent: Depreciation (120,353 ) (295,775 ) Total deferred tax liabilities (120,353 ) (295,775 ) Net deferred tax assets 85,180,124 82,105,085 Less: valuation allowance (85,180,124 ) (82,105,085 ) Total $ - $ - The Company has determined, based upon its history, that it is probable that future taxable income may The acquired NOL carryforwards from zPREDICTA experienced an ownership change as defined in Section 382 2019 December 2013. may December 2013, not At December 31, 2020, 2021, 382 2022 December 31, 2020. 2021 2020 2020 December 31, 2020, At December 31, 2021, 2022, 382 2023 December 31, 2021. 2022 December 31, 2021, Tax years subsequent to 2001 The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2021 2020, no

Note 10 - Goodwill and Intangib

Note 10 - Goodwill and Intangibles	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 10 Goodwill and Intangibles Intangible Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Amortization expense was $374,328 and $313,709 in 2021 2020, 360, Property, Plant and Equipment may not may not not As of December 31, 2021, December 31, 2020. The components of intangible assets were as follows: December 31, 2021 December 31, 2020 Gross Accumulated Amortization Impairment Net Gross Accumulated Amortization Net Patents & Trademarks $ 453,314 $ (230,572 ) $ - $ 222,742 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 6,382,000 (432,733 ) (2,485,725 ) 3,463,542 2,882,000 (252,175 ) 2,629,825 Customer Relationships 645,000 (410,000 ) (37,083 ) 197,917 445,000 (259,583 ) 185,417 Tradename 478,000 (29,344 ) (370,740 ) 77,917 398,000 (5,452 ) 392,548 Total $ 7,958,314 $ (1,102,649 ) $ (2,893,548 ) $ 3,962,118 $ 4,126,421 $ (728,320 ) $ 3,398,101 The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2021: Year ending December 31, Expense 2022 $ 411,609 2023 411,610 2024 411,610 2025 409,526 2026 391,610 Thereafter 1,926,153 Total $ 3,962,118 Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment and intangible assets with estimable useful lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of such an asset may not The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeded its estimated undiscounted future cash flows, the Company recorded an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined by utilizing discounted cash flow techniques. The Company prepared an undiscounted cash flow as of December 31, 2021 360. not December 31, 2021. December 31, 2021 no December 31, 2021. 2020. Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not In the Helomics acquisition, the Company recorded goodwill of $23,790,290. The goodwill was recorded to the Helomics segment which represents a single reporting unit. As a part of the annual impairment testing as of December 31, 2019, not not first may In testing goodwill for impairment as of September 30, 2020, September 30, 2020. 2017 04, Simplifying the Test for Goodwill Impairment September 30, 2020 When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 20-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 3.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 25% based on management’s best estimate of the after-tax weighted average cost of capital. The discount rate included a Company specific risk premium of 10% for risks related to the term of the forecasts. In testing goodwill for impairment as of December 31, 2020, December 31, 2020. December 31, 2020 0.5% 0.5% December 31, 2020, When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value in 2020 During the third 2021, September 30, 2021, September 30, 2021. The quantitative review as of September 30, 2021 September 30, 2021, When evaluating the fair value of Helomics reporting unit the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 10-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures); (b) an estimated terminal value using a terminal year growth rate of 4.0% determined based on the growth prospects of the reporting unit; and (c) a discount rate of 15% based on management’s best estimate of the after-tax weighted average cost of capital. The Company further used a probability weighting of various forecasts to address forecast risk. Goodwill of $6,857,790 was recognized in the zPREDICTA acquisition and represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and represents the future economic benefits and synergies arising from the transaction. None Note 2 zPREDICTA acquisition The following tables present changes in the carrying value of goodwill our consolidated balance sheet: Goodwill balance at December 31, 2019 $ 15,690,290 Impairment (12,876,498 ) Goodwill balance at December 31, 2020 $ 2,813,792 Impairment (2,813,792 ) Acquisition of zPREDICTA 6,857,790 Goodwill balance at December 31, 2021 $ 6,857,790 The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 1

Note 11 - Leases

Note 11 - Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 11 LEASES Our corporate offices are located in Eagan, Minnesota. The lease as amended has a three January 31, 2021. December 31, 2020 one January 31, 2022, second six July 31, 2022. The offices of our Helomics subsidiary are located in Pittsburgh, Pennsylvania. The lease, as amended, has a three February 28, 2023. zPREDICTA’s offices are located in San Jose, California. We lease approximately 1,236 square feet at this location. The lease is month-to-month tenancy. Soluble Biotech’s offices are located in Birmingham, Alabama. We lease approximately 4,314 square feet at this location. The lease is effective through August 25, 2025. TumorGenesis’s offices are located in Salem, Massachusetts. We lease approximately 1,450 square feet at this location. The lease is effective through May 31, 2023. Skyline Medical Europe’s offices were located in Belgium. The Company leased around 2,000 square feet at this location, 750 square feet of which is used for storage and 1,250 square feet is used for office space. The lease was terminated in the fourth 2020. Lease expense under operating lease arrangements was $595,669 and $565,581 for 2021 2020, The following table summarizes other information related to the Company’s operating leases: December 31, 2021 December 31, 2020 Weighted average remaining lease term – operating leases in years 1.69 2.33 Weighted average discount rate – operating leases 8% 8% The Company’s lease obligation as of December 31, 2021 2022 $ 751,345 2023 188,931 2024 71,420 2025 48,552 Total lease payments 1,060,248 Less interest 180,922 Present value of lease liabilities $ 879,326

Note 12 - Property, Plant and E

Note 12 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 12 Property, Plant and Equipment Fixed Assets The Company’s fixed assets consist of the following: December 31, 2021 December 31, 2020 Computers, software and office equipment $ 517,488 $ 1,862,669 Laboratory equipment 3,456,091 2,811,011 Leasehold improvements 428,596 315,297 Manufacturing tooling 121,120 108,956 Demo equipment 56,614 56,614 Total 4,579,909 5,154,547 Less: Accumulated depreciation 2,068,338 1,331,847 Total fixed assets, net $ 2,511,571 $ 3,822,700 Upon retirement or sale or fixed assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations expense. Maintenance and repairs are expensed as incurred. The Company prepared an undiscounted cash flow as of December 31, 2021 360. not December 31, 2021. December 31, 2021 no December 31, 2021. Depreciation expense was $965,973 and $711,139 in 2021 2020,

Note 13 - Segments

Note 13 - Segments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 13 SEGMENTS The Company has determined its reportable segments in accordance with ASC 280, Segment Reporting During the third 2020, 280 10 50 3, first third 2020. The Company has four reportable segments: Helomics, zPREDICTA, Soluble and Skyline. See discussion of revenue recognition in Note 1 The table below summarizes the Company’s segment reporting as of and for years ended December 31, 2021 2020. Year Ended December 31, 2021 Skyline Helomics Soluble zPREDICTA Corporate Total Revenue $ 1,169,811 $ 13,367 $ 233,293 $ 90 $ 4,119 $ 1,420,680 Depreciation and Amortization (30,002 ) (886,642 ) (366,713 ) (40,625 ) (16,319 ) (1,340,301 ) Impairment expense goodwill - (2,813,792 ) - - - (2,813,792 ) Impairment expense intangibles - (2,893,548 ) - - - (2,893,548 ) Impairment expense acquired software - (1,249,727 ) - - - (1,249,727 ) Net loss $ (520,822 ) $ (11,326,948 ) $ (1,251,564 ) $ 531,446 $ (7,089,286 ) $ (19,657,174 ) December 31, 2021 Skyline Helomics Soluble zPREDICTA Corporate Total Assets $ 906,977 $ 1,802,792 $ 1,742,445 $ 10,782,568 $ 28,536,489 $ 43,771,271 Year Ended December 31, 2020 Skyline Helomics Soluble Corporate Total Revenue $ 1,185,214 $ 64,188 $ 2,870 $ - $ 1,252,272 Depreciation and Amortization (38,310 ) (761,105 ) (184,071 ) (41,362 ) (1,024,848 ) Impairment expense - (12,876,498 ) - - (12,876,498 ) Net loss $ (1,132,251 ) $ (15,112,131 ) $ (671,367 ) $ (8,968,648 ) $ (25,884,397 ) December 31, 2020 Skyline Helomics Soluble Corporate Total Assets $ 1,191,439 $ 9,773,902 $ 1,883,585 $ 211,510 $ 13,060,436 In 2021, December 31, 2021,

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 14 RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s former directors, Richard L. Gabriel, is the Chief Operating Officer of GLG Pharma (“GLG”) and serves as a director of that firm. The Company and GLG have a partnership agreement for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no Richard L. Gabriel was also contracted as the Chief Operating Officer for TumorGenesis. Through April 1, 2019, six May 1, 2019, one three Effective May 1, 2021, not

Note 15 - Retirement Savings Pl

Note 15 - Retirement Savings Plans	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15 RETIREMENT SAVINGS PLANS The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 2019 2018, 2021 2020, no 2021 2020.

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 16 SUBSEQUENT EVENTS Equity Line Agreement During the first 2022 March 28,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc., (the “Company” or “Predictive” or “we”) filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name to Predictive Oncology Inc. on June 10, 2019, June 13, 2019. The Company operates in four The Company had cash and cash equivalents of $28,202,615 as of December 31, 2021. December 31, 2021, twelve may
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak The current COVID- 19 19 19 may 19 may 19 10
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the financial statements and during the reporting period. Actual results could materially differ from those estimates.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. The reclassifications had no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the current status of individual accounts. Amounts recorded in accounts receivable on the consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not December 31, 2021 2020.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives 3 Note 10 Goodwill and Intangibles The acquisition of zPREDICTA was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the acquisition date. The majority of the inputs used in the discounted cash flow model, the relief-from-royalty method under the income approach, the distributor method under the income approach and the multi-period excess earnings method under the income approach, each are unobservable and thus are considered to be Level 3 Note 2 zPREDICTA Acquisition
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not The Company prepared an undiscounted cash flow as of December 31, 2021 360. not December 31, 2021. December 31, 2021 no December 31, 2021. 10 The Company also prepared an undiscounted cash flow as of December 31, 2020 no December 31, 2020.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, 3 1 3
Lessee, Leases [Policy Text Block]	Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing C one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2021 2020, The Company’s deferred revenues related primarily to our zPREDICTA contract research revenue and maintenance plans of our Skyline Medical operating segment. As of December 31, 2021 2020, Practical Expedients The Company has elected the practical expedient not
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the Year Ended December 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.66% 0.13% - 1.78% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% - 87% Risk-free interest rate 0.42% - 0.69% 0.135% - 0.79% Expected life (years) 5/ 5.5 5/ 5.5
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $315,850 and $372,710 for the years ended 2021 2020,
Other Expense Policy [Policy Text Block]	Other Expense Other expense consisted primarily of interest expense, payment penalties, amortization of original issue discounts, and loss on debt extinguishment associated to the Company’s notes payable.
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2001
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one December 31, 2021. not
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not The Company has evaluated all of its activities and concluded that no Note 16 Subsequent Events

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers, software and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	For the Year Ended December 31, 2021 2020 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% - 89.6% 82.6% - 87% Risk-free interest rate 0.93% - 1.66% 0.13% - 1.78% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 84.8% 82.6% - 87% Risk-free interest rate 0.42% - 0.69% 0.135% - 0.79% Expected life (years) 5/ 5.5 5/ 5.5

Note 2 - zPredicta Acquisition

Note 2 - zPredicta Acquisition (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash consideration $ 10,015,941 Assets acquired: Cash 425,727 Accounts receivable 76,549 Prepaid expenses 25,733 Intangible assets 3,780,000 Liabilities assumed: Accrued expenses (408,825 ) Deferred tax liability (661,658 ) Deferred revenue (79,375 ) Goodwill $ 6,857,790
Business Acquisition, Pro Forma Information [Table Text Block]	2021 2020 Unaudited Unaudited Revenue $ 2,429,786 $ 1,815,560 Net loss attributable to common shareholders $ (18,878,432 ) $ (26,946,564 )

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2021 December 31, 2020 Finished goods $ 193,287 $ 95,898 Raw materials 183,410 151,366 Work-In-Process 10,987 42,271 Total $ 387,684 $ 289,535

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Sales of Stock [Table Text Block]	Offering Closing Date Shares Sale Price per Share* Investor Warrants Exercise Price per Share investor Warrants Placement Agent Warrants Exercise Price per Share Placement Agent Warrants Gross Proceeds of Offering Net Proceeds of Offering January 12, 2021 (registered direct) 3,650,840 $ 0.842 1,825,420 $ 0.80 273,813 $ 1.0525 $ 3,074,007 $ 2,731,767 January 21, 2021 (registered direct) 2,200,000 $ 1.00 1,100,000 $ 1.00 165,000 $ 1.25 $ 2,200,000 $ 1,932,050 January 26, 2021 (registered direct) 3,414,970 $ 1.20 1,707,485 $ 1.20 256,123 $ 1.50 $ 4,097,964 $ 3,668,687 February 16, 2021 (registered direct) 4,222,288 $ 1.75 2,111,144 $ 2.00 316,672 $ 2.1875 $ 7,389,004 $ 6,679,989 February 23, 2021 (private placement) 9,043,766 $ 1.95 4,521,883 $ 2.00 678,282 $ 2.4375 $ 17,635,344 $ 16,064,739 June 16, 2021 (registered direct) 15,520,911 $ 1.375 15,520,911 $ 1.25 1,164,068 $ 1.71875 $ 21,341,252 $ 19,446,296 Total 38,057,775 26,786,843 2,853,958 $ 55,737,571 $ 50,523,528
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2019 766,424 $ 11.34 2,171,610 $ 15.26 Issued 319,851 1.03 8,097,468 1.55 Forfeited (72,728 ) 10.58 (128,710 ) 95.11 Exercised - - (2,786,992 ) 0.79 Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 1.99 Issued 147,230 1.06 29,640,801 1.44 Forfeited (92,593 ) 8.64 - - Expired - - (25,233 ) 10.00 Exercised (5,313 ) 0.74 (5,269,059 ) 0.86 Outstanding at December 31, 2021 1,062,871 $ 4.83 31,699,885 $ 1.66
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Exercise Prices Shares Weighted Average Remaining Life Options: 0.72 – 1.10 335,876 9.31 $1.15 – 1.64 356,673 8.36 $2.610 – 8.41 214,937 8.15 $10.10 – 5,962.50 155,385 5.99 Total 1,062,871 Warrants: $0.80-1.72 21,468,599 3.31 $1.80 – 2.18 8,451,287 4.50 $2.25 – 10.00 1,555,778 3.37 $10.71 – 22.50 224,221 2.94 Total 31,699,885
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year Shares Price 2012 114 $1.54 – $1,500.00 2013 146 1.54 – 5,962.50 2014 84 1.54 – 3,468.75 2015 394 1.54 – 862.50 2016 9,174 1.54 – 42.50 2017 214,555 1.54 – 21.00 2018 78,325 1.54 – 13.50 2019 314,963 1.54 – 7.50 2020 303,199 0.73 – 3.48 2021 141,917 0.72 – 1.47 Total 1,062,871 $0.72 – $5,962.50 Year Shares Price 2017 108,435 $10.71 – $22.50 2018 196,946 8.36 – 13.125 2019 1,690,286 0.845 – 11.80 2020 2,010,144 0.845 – 2.992 2021 27,694,074 0.80 – 2.992 Total 31,699,885 $0.80 – $22.50

Note 6 - Notes Payable (Tables)

Note 6 - Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Short-term Debt [Table Text Block]	Due Date December 31, 2021 December 31, 2020 2018 Investor loan March 31, 2021 $ - $ 1,721,776 Promissory note 2019 March 27, 2021 - 1,490,833 Promissory note 2020 March 31, 2021 - 1,464,146 Total Notes Payable, gross - 4,676,755 Less: Unamortized discount - 244,830 Total Notes Payable, net $ - $ 4,431,925

Note 7 - Derivatives (Tables)

Note 7 - Derivatives (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2019 $ 50,989 Derivative instrument recognized for A, B and Agent Warrants 2,669,995 Derivative instrument related to Promissory Note 2020 120,921 Derivative instrument recognized for May 2020 Warrants 1,324,184 Derivative instrument recognized for June 2020 Warrants 1,749,721 Derivative instrument related to Promissory Note 2020 20,542 Reclassification of Warrant liabilities to Equity on exercise (1,701,756 ) Reclassification of Warrant liabilities to Equity (2,669,408 ) Derivative instrument related to September 30 debt amendments 495,100 Gain recognized to revalue derivative instrument at fair value (1,765,906 ) Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (164,902 ) Derivative liability balance at December 31, 2021 $ 129,480

Note 8 - Loss Per Share (Tables

Note 8 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2021 2020 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (19,657,174 ) $ (26,438,684 ) Denominator: Weighted average common shares outstanding-basic 54,876,044 11,950,154 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 54,876,044 11,950,154 Loss per common share-basic and diluted $ (0.36 ) $ (2.21 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 Options 1,062,871 1,013,547 Warrants 31,699,885 7,353,376 Convertible debt - 1,107,544 Preferred stock: Series B 79,246 79,246

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 Statutory federal income tax benefit $ 4,266,955 $ 5,434,463 State tax benefit, net of federal taxes 793,282 578,746 Foreign tax benefit - 62,146 Foreign operations tax rate differential - (44,120 ) State rate adjustment 5,153 65,112 Nondeductible/nontaxable items (260,768 ) (268,968 ) Goodwill impairment (605,420 ) (2,762,014 ) NOL adjustments (612,588 ) (1,141,662 ) Other 150,083 (461,020 ) Valuation allowance increase (3,075,039 ) (1,462,683 ) Total income tax benefit $ 661,658 $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2021 December 31, 2020 Deferred tax assets: Noncurrent: Inventory $ - $ 7,196 Compensation accruals 58,829 63,846 Accruals and reserves 50,537 162,628 Deferred revenue 26,198 11,641 Charitable contribution carryover 1,095 4,331 Derivatives 27,859 63,145 Intangibles 700,876 295,941 Right of use asset 18,543 13,861 NSQO compensation 1,602,429 1,738,217 NOL and credits 82,814,111 80,038,356 Total deferred tax assets 85,300,477 82,400,860 Deferred tax liabilities: Noncurrent: Depreciation (120,353 ) (295,775 ) Total deferred tax liabilities (120,353 ) (295,775 ) Net deferred tax assets 85,180,124 82,105,085 Less: valuation allowance (85,180,124 ) (82,105,085 ) Total $ - $ -

Note 10 - Goodwill and Intang_2

Note 10 - Goodwill and Intangibles (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2021 December 31, 2020 Gross Accumulated Amortization Impairment Net Gross Accumulated Amortization Net Patents & Trademarks $ 453,314 $ (230,572 ) $ - $ 222,742 $ 401,421 $ (211,110 ) $ 190,311 Developed Technology 6,382,000 (432,733 ) (2,485,725 ) 3,463,542 2,882,000 (252,175 ) 2,629,825 Customer Relationships 645,000 (410,000 ) (37,083 ) 197,917 445,000 (259,583 ) 185,417 Tradename 478,000 (29,344 ) (370,740 ) 77,917 398,000 (5,452 ) 392,548 Total $ 7,958,314 $ (1,102,649 ) $ (2,893,548 ) $ 3,962,118 $ 4,126,421 $ (728,320 ) $ 3,398,101
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2022 $ 411,609 2023 411,610 2024 411,610 2025 409,526 2026 391,610 Thereafter 1,926,153 Total $ 3,962,118
Schedule of Goodwill [Table Text Block]	Goodwill balance at December 31, 2019 $ 15,690,290 Impairment (12,876,498 ) Goodwill balance at December 31, 2020 $ 2,813,792 Impairment (2,813,792 ) Acquisition of zPREDICTA 6,857,790 Goodwill balance at December 31, 2021 $ 6,857,790

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	December 31, 2021 December 31, 2020 Weighted average remaining lease term – operating leases in years 1.69 2.33 Weighted average discount rate – operating leases 8% 8%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 $ 751,345 2023 188,931 2024 71,420 2025 48,552 Total lease payments 1,060,248 Less interest 180,922 Present value of lease liabilities $ 879,326

Note 12 - Property, Plant and_2

Note 12 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2021 December 31, 2020 Computers, software and office equipment $ 517,488 $ 1,862,669 Laboratory equipment 3,456,091 2,811,011 Leasehold improvements 428,596 315,297 Manufacturing tooling 121,120 108,956 Demo equipment 56,614 56,614 Total 4,579,909 5,154,547 Less: Accumulated depreciation 2,068,338 1,331,847 Total fixed assets, net $ 2,511,571 $ 3,822,700

Note 13 - Segments (Tables)

Note 13 - Segments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2021 Skyline Helomics Soluble zPREDICTA Corporate Total Revenue $ 1,169,811 $ 13,367 $ 233,293 $ 90 $ 4,119 $ 1,420,680 Depreciation and Amortization (30,002 ) (886,642 ) (366,713 ) (40,625 ) (16,319 ) (1,340,301 ) Impairment expense goodwill - (2,813,792 ) - - - (2,813,792 ) Impairment expense intangibles - (2,893,548 ) - - - (2,893,548 ) Impairment expense acquired software - (1,249,727 ) - - - (1,249,727 ) Net loss $ (520,822 ) $ (11,326,948 ) $ (1,251,564 ) $ 531,446 $ (7,089,286 ) $ (19,657,174 ) December 31, 2021 Skyline Helomics Soluble zPREDICTA Corporate Total Assets $ 906,977 $ 1,802,792 $ 1,742,445 $ 10,782,568 $ 28,536,489 $ 43,771,271 Year Ended December 31, 2020 Skyline Helomics Soluble Corporate Total Revenue $ 1,185,214 $ 64,188 $ 2,870 $ - $ 1,252,272 Depreciation and Amortization (38,310 ) (761,105 ) (184,071 ) (41,362 ) (1,024,848 ) Impairment expense - (12,876,498 ) - - (12,876,498 ) Net loss $ (1,132,251 ) $ (15,112,131 ) $ (671,367 ) $ (8,968,648 ) $ (25,884,397 ) December 31, 2020 Skyline Helomics Soluble Corporate Total Assets $ 1,191,439 $ 9,773,902 $ 1,883,585 $ 211,510 $ 13,060,436

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 28,202,615	$ 678,332
Long-term Debt, Total	0
Accounts Receivable, Allowance for Credit Loss, Current	0	0
Impairment of Intangible Assets (Excluding Goodwill), Total	2,893,548	0
Impairment of Intangible Assets, Software Acquired	1,249,727	0
Accounts Receivable, after Allowance for Credit Loss, Total	354,196	256,878
Contract with Customer, Liability, Total	186,951	53,028
Research and Development Expense, Total	315,850	$ 372,710
Unrecognized Tax Benefits, Ending Balance	0
Other Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 0

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2021
Demo Equipment [Member]
Computers, software and office equipment (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Computers, software and office equipment (Year)	3 years
Minimum [Member] | Leasehold Improvements [Member]
Computers, software and office equipment (Year)	2 years	[1]
Minimum [Member] | Manufacturing Tooling [Member]
Computers, software and office equipment (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Computers, software and office equipment (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Computers, software and office equipment (Year)	10 years
Maximum [Member] | Leasehold Improvements [Member]
Computers, software and office equipment (Year)	5 years	[1]
Maximum [Member] | Manufacturing Tooling [Member]
Computers, software and office equipment (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Computers, software and office equipment (Year)	10 years
[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected dividend yield	0.00%	0.00%
Expected life (years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Minimum [Member]
Expected stock price volatility	84.80%	82.60%
Risk-free interest rate	0.93%	0.13%
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.826
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0042	0.00135
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5	5
Maximum [Member]
Expected stock price volatility	89.60%	87.00%
Risk-free interest rate	1.66%	1.78%
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.87
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0069	0.0079
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	5.5

Note 2 - zPredicta Acquisitio_2

Note 2 - zPredicta Acquisition (Details Textual) - USD ($)	Nov. 24, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Ending Balance		$ 6,857,790	$ 2,813,792	$ 15,690,290
zPREDICTA [Member]
Payments to Acquire Businesses, Gross	$ 10,015,941
Business Combination, Acquisition Related Costs		$ 895,297
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,780,000
Goodwill, Ending Balance	6,857,790
zPREDICTA [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	80,000
Finite-Lived Intangible Asset, Useful Life (Year)		4 years
zPREDICTA [Member] | Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,500,000
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
zPREDICTA [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 200,000
Finite-Lived Intangible Asset, Useful Life (Year)		10 years

Note 2 - zPredicta Acquisitio_3

Note 2 - zPredicta Acquisition - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Nov. 24, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill, Ending Balance		$ 6,857,790	$ 2,813,792	$ 15,690,290
zPREDICTA [Member]
Payments to Acquire Businesses, Gross	$ 10,015,941
Cash	425,727
Accounts receivable	76,549
Prepaid expenses	25,733
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	3,780,000
Accrued expenses	(408,825)
Deferred tax liability	(661,658)
Deferred revenue	(79,375)
Goodwill, Ending Balance	$ 6,857,790

Note 2 - zPredicta Acquisitio_4

Note 2 - zPredicta Acquisition - Pro Form Information (Details) - zPREDICTA [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 2,429,786	$ 1,815,560
Net loss attributable to common shareholders	$ (18,878,432)	$ (26,946,564)

Note 3 - Inventories - Schedule

Note 3 - Inventories - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finished goods	$ 193,287	$ 95,898
Raw materials	183,410	151,366
Work-In-Process	10,987	42,271
Total	$ 387,684	$ 289,535

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Sep. 14, 2020USD ($)$ / sharesshares	Jul. 01, 2020USD ($)shares	Jun. 12, 2020shares	May 27, 2020USD ($)shares	May 08, 2020USD ($)$ / sharesshares	Apr. 21, 2020USD ($)$ / sharesshares	Apr. 04, 2020shares	Mar. 18, 2020$ / sharesshares	Oct. 29, 2019$ / shares	Oct. 24, 2019USD ($)shares	Jun. 30, 2020USD ($)$ / sharesshares	May 31, 2020shares	Mar. 18, 2020USD ($)$ / sharesshares	Apr. 30, 2019shares	Feb. 28, 2021shares	Mar. 31, 2020shares	Sep. 30, 2019USD ($)shares	Sep. 30, 2021	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Aug. 17, 2021$ / sharesshares	Aug. 10, 2021shares	Jun. 30, 2021shares	Sep. 23, 2020$ / sharesshares	Jan. 31, 2020USD ($)	Jul. 15, 2019USD ($)
Common Stock, Shares Authorized (in shares)																			200,000,000	100,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.01																		$ 0.01	$ 0.01	$ 0.01			$ 0.01
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds															7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds															1.00%
Proceeds from Warrant Exercises | $																			$ 4,513,871	$ 1,935,855
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $																			0	5,057,919
Debt Instrument, Face Amount | $																			0	4,676,755
Fixed Assets Acquired for Notes Receivable and Common Stock | $																			0	2,962,767
Fair Value Adjustment of Warrants | $																			$ (164,902)	$ (1,765,907)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)																			949,615	977,420
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares																			$ 5.27	$ 5.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)																			8 years 1 month 20 days	8 years 9 months 3 days
Class of Warrant or Right Number of Warrants Vested and Exercisable (in shares)																			31,725,118	7,353,376
Share-based Payment Arrangement, Expense | $																			$ 146,714	$ 780,269
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $																			$ 70,324
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)																			19 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio									0.1
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total | $				$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				125,000
Fixed Assets Acquired for Notes Receivable and Common Stock | $				$ 1,290,000
Asset Purchase Shares Issued Shares Escrow Deposit To Be Released Upon Six Months Anniversary Of Closing (in shares)				25,000
Asset Purchase Shares Issued, Shares Escrow Deposit To Be Released Upon Nine Months Anniversary Of Closing (in shares)				25,000
Business Acquisition, Right to Reclaim, Number of Shares (in shares)				10,000
Asset Purchase Agreement With Quantitative Medicine [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		954,719
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $		$ 1,470,267
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow (in shares)		477,359
Asset Purchase Agreement With Quantitative Medicine [Member] | Carnegie Mellon University [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		207,144
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1.43
DrSchwartz Notes [Member]
Debt Instrument, Face Amount | $						$ 2,115,000																			$ 2,115,000	$ 1,920,000
DrSchwartz Notes [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						1,583,481
Conversion from Series D Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)							3,500,000
Conversion of Stock, Shares Issued (in shares)							350,004
Conversion from Series E Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)												207.7				50
Conversion of Stock, Shares Issued (in shares)			1,257,416													141,191
Conversion of Stock, Shares Issued, Percentage of Outstanding Shares			11.80%									0.05686%
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			207.7
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)														3,500,000
Convertible Preferred Stock, Conversion Rate														10
Series E Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Rate																	0.056857
Stock Issued During Period, Shares, Convertible Preferred Shares Issued (in shares)																	258
Preferred Stock, Beneficial Conversion Feature | $																	$ 289,935
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																			$ 22.50
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																			10 years
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																		3 years
Stock Incentive Plan 2012 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																						3,250,000	1,500,000
Investor Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)																			5,269,059
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																			$ 0.86
Proceeds from Warrant Exercises | $																			$ 4,513,871
Placement Agent Warrants [Member]
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold															7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price															125.00%
Warrants issued with Private Placement [Member]
Warrants and Rights Outstanding, Term (Year)					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.45			$ 0.001					$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,396,826			1,390,166					1,390,166
Price of Warrant (in dollars per share) | $ / shares								$ 2.12
Proceeds from Issuance or Sale of Equity, Total | $					$ 2,200,001
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $					$ 1,930,100
Shares Issued, Price Per Share (in dollars per share) | $ / shares					$ 1.575
Series A Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								5 years 6 months					5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)								2 years					2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.88					$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,650,166					1,650,166
Prefunded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.0001					$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,390,166					1,390,166
Price of Warrant (in dollars per share) | $ / shares													$ 2.12
June 2020 Warrant [Member]
Warrants and Rights Outstanding, Term (Year)											5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.80													$ 1.88
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								1,396,826
Class of Warrant or Right, Exercise Price of Warrants or Rights, Amended Price (in dollars per share) | $ / shares																								$ 0.8457
Class Of Warrant Or Right, Purchase Price Per Warrant (in dollars per share) | $ / shares											$ 0.125
Class of Warrant or Right, Percentage of Shares Issued Pursuant to Exercise of Existing Warrant											100.00%
Proceeds from Issuance and Exercise of Warrants | $											$ 2,130,701
Proceeds from Issuance and Exercise of Warrants, Net | $											$ 1,865,800
Warrant Issued in Connection With May 2020 Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.45
Class of Warrant or Right Issued During Period (in shares)											1,396,826
Warrants Issued in Connection With Helomics Acquisition [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.845								$ 10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,424,506
Fair Value Adjustment of Warrants | $	$ 554,287
Registered Direct Offerings [Member]
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Value, New Issues | $																			15,012,492
Registered Direct Offerings [Member] | Investor Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
Registered Direct Offerings [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years
Private Placement [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares					$ 0.01
Number of Warrants Issued to Each Investor, Per Two Shares of Stock Purchased (in shares)															1
Stock Issued During Period, Shares, New Issues (in shares)					1,396,826			260,000
Stock Issued During Period, Value, New Issues | $																			16,064,739
Sale of Stock, Price Per Share (in dollars per share) | $ / shares								$ 2.121					$ 2.121
Proceeds from Issuance or Sale of Equity, Total | $													$ 3,498,612
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $													$ 3,127,818
Private Placement [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															5 years 6 months
June 2021 Offering [Member]
Stock Issued During Period, Value, New Issues | $																			$ 19,446,296
June 2021 Offering [Member] | Placement Agent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)															3 years
Equity Line Purchase Agreement [Member]
Issuance or Sale of Equity, Can Be Raised | $										$ 15,000,000
Stock Issued During Period, Shares, New Issues (in shares)										104,651									647,504	4,231,073
Stock Issued During Period, Value, New Issues | $										$ 450,000									$ 675,590	$ 4,891,348
Sale of Stock, Remaining Available Balance | $																			$ 9,113,829

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Net proceeds		$ 0	$ 5,057,919
Investor Warrants [Member]
Warrants issued, exercise price (in dollars per share)		$ 0.86
January 12, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		3,650,840
Shares issued, price per share (in dollars per share)	[1]	$ 0.842
Gross proceeds		$ 3,074,007
Net proceeds		$ 2,731,767
Shares issued (in shares)		3,650,840
Shares issued, price per share (in dollars per share)	[1]	$ 0.842
January 12, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,825,420
Warrants issued, exercise price (in dollars per share)		$ 0.80
January 12, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		273,813
Warrants issued, exercise price (in dollars per share)		$ 1.0525
January 21, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		2,200,000
Shares issued, price per share (in dollars per share)	[1]	$ 1
Gross proceeds		$ 2,200,000
Net proceeds		$ 1,932,050
Shares issued (in shares)		2,200,000
Shares issued, price per share (in dollars per share)	[1]	$ 1
January 21, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,100,000
Warrants issued, exercise price (in dollars per share)		$ 1
January 21, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		165,000
Warrants issued, exercise price (in dollars per share)		$ 1.25
January 26, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		3,414,970
Shares issued, price per share (in dollars per share)	[1]	$ 1.20
Gross proceeds		$ 4,097,964
Net proceeds		$ 3,668,687
Shares issued (in shares)		3,414,970
Shares issued, price per share (in dollars per share)	[1]	$ 1.20
January 26, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		1,707,485
Warrants issued, exercise price (in dollars per share)		$ 1.20
January 26, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		256,123
Warrants issued, exercise price (in dollars per share)		$ 1.50
February 16, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		4,222,288
Shares issued, price per share (in dollars per share)	[1]	$ 1.75
Gross proceeds		$ 7,389,004
Net proceeds		$ 6,679,989
Shares issued (in shares)		4,222,288
Shares issued, price per share (in dollars per share)	[1]	$ 1.75
February 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		2,111,144
Warrants issued, exercise price (in dollars per share)		$ 2
February 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		316,672
Warrants issued, exercise price (in dollars per share)		$ 2.1875
Febuary 23, 2021 Private Placement [Member]
Shares issued (in shares)		9,043,766
Shares issued, price per share (in dollars per share)	[1]	$ 1.95
Gross proceeds		$ 17,635,344
Net proceeds		$ 16,064,739
Shares issued (in shares)		9,043,766
Shares issued, price per share (in dollars per share)	[1]	$ 1.95
Febuary 23, 2021 Private Placement [Member] | Investor Warrants [Member]
Warrants issued (in shares)		4,521,883
Warrants issued, exercise price (in dollars per share)		$ 2
Febuary 23, 2021 Private Placement [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		678,282
Warrants issued, exercise price (in dollars per share)		$ 2.4375
June 16, 2021 Registered Direct Offering [Member]
Shares issued (in shares)		15,520,911
Shares issued, price per share (in dollars per share)		$ 1.375
Gross proceeds		$ 21,341,252
Net proceeds		$ 19,446,296
Shares issued (in shares)		15,520,911
Shares issued, price per share (in dollars per share)		$ 1.375
June 16, 2021 Registered Direct Offering [Member] | Investor Warrants [Member]
Warrants issued (in shares)		15,520,911
Warrants issued, exercise price (in dollars per share)		$ 1.25
June 16, 2021 Registered Direct Offering [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		1,164,068
Warrants issued, exercise price (in dollars per share)		$ 1.71875
Total Issuances [Member]
Shares issued (in shares)		38,057,775
Gross proceeds		$ 55,737,571
Net proceeds		$ 50,523,528
Shares issued (in shares)		38,057,775
Total Issuances [Member] | Investor Warrants [Member]
Warrants issued (in shares)		26,786,843
Total Issuances [Member] | Placement Agent Warrants [Member]
Warrants issued (in shares)		2,853,958
[1]	Sale price includes one share and a warrant to purchase one-half share.

Note 4 - Stockholders' Equity_5

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares Outstanding (in shares)	1,062,871
Warrant [Member]
Number of Shares Outstanding (in shares)	7,353,376	2,171,610
Average Exercise Price Outstanding (in dollars per share)	$ 1.99	$ 15.26
Number of Shares Issued (in shares)	29,640,801	8,097,468
Average Exercise Price Issued (in dollars per share)	$ 1.44	$ 1.55
Number of Shares Forfeited (in shares)	0	(128,710)
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 95.11
Number of Shares Exercised (in shares)	(5,269,059)	(2,786,992)
Average Exercise Price Exercised (in dollars per share)	$ 0.86	$ 0.79
Expired (in shares)	(25,233)
Expired (in dollars per share)	$ 10
Number of Shares Outstanding (in shares)	31,699,885	7,353,376
Average Exercise Price Outstanding (in dollars per share)	$ 1.66	$ 1.99
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	1,013,547	766,424
Average Exercise Price Outstanding (in dollars per share)	$ 5.41	$ 11.34
Number of Shares Issued (in shares)	147,230	319,851
Average Exercise Price Issued (in dollars per share)	$ 1.06	$ 1.03
Number of Shares Forfeited (in shares)	(92,593)	(72,728)
Average Exercise Price Forfeited (in dollars per share)	$ 8.64	$ 10.58
Number of Shares Exercised (in shares)	(5,313)	0
Average Exercise Price Exercised (in dollars per share)	$ 0.74	$ 0
Expired (in shares)	0
Expired (in dollars per share)	$ 0
Number of Shares Outstanding (in shares)	1,062,871	1,013,547
Average Exercise Price Outstanding (in dollars per share)	$ 4.83	$ 5.41

Note 4 - Stockholders' Equity_6

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Shares, options (in shares) | shares	1,062,871
Shares, warrants (in shares) | shares	31,699,885
Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.80
Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrant One [Member]
Shares, warrants (in shares) | shares	21,468,599
Weighted average remaining life, warrants (Year)	3 years 3 months 21 days
Warrant One [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 80
Warrant One [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 1.72
Warrant Two [Member]
Shares, warrants (in shares) | shares	8,451,287
Weighted average remaining life, warrants (Year)	4 years 6 months
Warrant Two [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 1.80
Warrant Two [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.18
Warrant Three [Member]
Shares, warrants (in shares) | shares	1,555,778
Weighted average remaining life, warrants (Year)	3 years 4 months 13 days
Warrant Three [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.25
Warrant Three [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10
Warrant Four [Member]
Shares, warrants (in shares) | shares	224,221
Weighted average remaining life, warrants (Year)	2 years 11 months 8 days
Warrant Four [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10.71
Warrant Four [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	22.50
Stock Options One [Member]
Options, lower limit (in dollars per share)	0.72
Options, upper limit (in dollars per share)	$ 1.10
Shares, options (in shares) | shares	335,876
Weighted average remaining life, options (Year)	9 years 3 months 21 days
Stock Options Two [Member]
Options, lower limit (in dollars per share)	$ 1.15
Options, upper limit (in dollars per share)	$ 1.64
Shares, options (in shares) | shares	356,673
Weighted average remaining life, options (Year)	8 years 4 months 9 days
Stock Options Three [Member]
Options, lower limit (in dollars per share)	$ 2.610
Options, upper limit (in dollars per share)	$ 8.41
Shares, options (in shares) | shares	214,937
Weighted average remaining life, options (Year)	8 years 1 month 24 days
Stock Options Four [Member]
Options, lower limit (in dollars per share)	$ 10.10
Options, upper limit (in dollars per share)	$ 5,962.50
Shares, options (in shares) | shares	155,385
Weighted average remaining life, options (Year)	5 years 11 months 26 days

Note 4 - Stockholders' Equity_7

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Dec. 31, 2021$ / sharesshares
Shares, options (in shares) | shares	1,062,871
Shares, warrants (in shares) | shares	31,699,885
Minimum [Member]
Price, options (in dollars per share)	$ 0.72
Warrants issued, exercise price (in dollars per share)	0.80
Maximum [Member]
Price, options (in dollars per share)	5,962.50
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrants 2017 [Member]
Shares, warrants (in shares) | shares	108,435
Warrants 2017 [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 10.71
Warrants 2017 [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 22.50
Warrants 2018 [Member]
Shares, warrants (in shares) | shares	196,946
Warrants 2018 [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 8.36
Warrants 2018 [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 13.125
Warrants 2019 [Member]
Shares, warrants (in shares) | shares	1,690,286
Warrants 2019 [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.845
Warrants 2019 [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 11.80
Warrants 2020 [Member]
Shares, warrants (in shares) | shares	2,010,144
Warrants 2020 [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.845
Warrants 2020 [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.992
Warrants 2021 [Member]
Shares, warrants (in shares) | shares	27,694,074
Warrants 2021 [Member] | Minimum [Member]
Warrants issued, exercise price (in dollars per share)	$ 0.80
Warrants 2021 [Member] | Maximum [Member]
Warrants issued, exercise price (in dollars per share)	$ 2.992
Stock Options 2012 [Member]
Shares, options (in shares) | shares	114
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1,500
Stock Options 2013 [Member]
Shares, options (in shares) | shares	146
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5,962.50
Stock Options 2014 [Member]
Shares, options (in shares) | shares	84
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 3,468.75
Stock Options 2015 [Member]
Shares, options (in shares) | shares	394
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 862.50
Stock Options 2016 [Member]
Shares, options (in shares) | shares	9,174
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 42.50
Stock Options 2017 [Member]
Shares, options (in shares) | shares	214,555
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 21
Stock Options 2018 [Member]
Shares, options (in shares) | shares	78,325
Stock Options 2018 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2018 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 13.50
Stock Options 2019 [Member]
Shares, options (in shares) | shares	314,963
Stock Options 2019 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.54
Stock Options 2019 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 7.50
Stock Options 2020 [Member]
Shares, options (in shares) | shares	303,199
Stock Options 2020 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0.73
Stock Options 2020 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 3.48
Stock Options 2021 [Member]
Shares, options (in shares) | shares	141,917
Stock Options 2021 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0.72
Stock Options 2021 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1.47

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - USD ($)	May 27, 2020	Dec. 31, 2019
Other Capitalized Property Plant and Equipment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total	$ 1,492,500
Asset Purchase Agreement with InventaBiotech and Its Subsidiaries, Soluble and BioDeth [Member]
Stock Issued During Period, Shares, Purchase of Assets (in shares)	125,000
Other Nonoperating Income	$ 1,290,000
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total		$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage		8.00%
Financing Receivable, Allowance for Credit Loss, Ending Balance		$ 1,037,524

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual) - USD ($)	Mar. 01, 2021	Feb. 24, 2021	Apr. 21, 2020	Apr. 20, 2020	Mar. 19, 2020	Feb. 05, 2020	Sep. 28, 2018	Jan. 31, 2020	Sep. 30, 2019	Feb. 27, 2019	Nov. 30, 2018	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 05, 2020	Mar. 05, 2020	Jul. 15, 2019	Dec. 31, 2018
Debt Instrument, Face Amount												$ 4,676,755			$ 0	$ 4,676,755
Gain (Loss) on Extinguishment of Debt, Total															0	541,867
Payments for Penalties															1,073,470	247,327
Debt Instrument, Unamortized Discount, Total												244,830			0	244,830
Repayments of Debt															4,162,744	1,472,389
Debt Conversion, Converted Instrument, Amount															0	$ 267,328
Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)								50,000
Investor of Promissory Note [Member]
Stock Issued During Period, Shares, New Issues (in shares)						46,875
Dr. Schwartz [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		100,401
Shares Issued, Price Per Share (in dollars per share)			$ 1.43
Stock Issued, Agreement, Not to be Transferred or Sold For Three Months (in shares)			766,740
Stock Issued, Agreement, Not to be Transferred or Sold for Six Months (in shares)			766,741
Dr. Schwartz [Member] | DrSchwartz Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		143,573
Conversion of Bridge Loan to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)																170,000
Promissory Note Exchange Agreement [Member] | Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Amount								$ 2,115,000
Conversion of Promissory Note Into Common Stock [Member]
Shares Issued, Price Per Share (in dollars per share)			$ 1.43
Bridge Loan Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							107,178
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 11.55
Warrant for Promissory Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									68,237
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 6.21
Warrants Issued With Promissory Note, One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						94,631
Warrants Issued With Promissory Note, Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		92,700
Warrants Issued With Promissory Note, Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																	92,700
Warrants Issued With Promissory Note [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 2.992
Dr. Schwartz Notes Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																			22,129
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																			$ 8.36
Convertible Promissory Note [Member]
Debt Instrument, Face Amount												1,721,776			$ 0	$ 1,721,776
Promissory Note [Member] | Chief Executive Officer [Member]
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Second Promissory Note [Member]
Debt Instrument, Face Amount						$ 1,450,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Debt Conversion, Original Debt, Amount												$ 503,354
Debt Conversion, Converted Instrument, Shares Issued (in shares)												1,075,911
Proceeds from Short-term Debt, Total						$ 400,000
Payments for Penalties																0
Penalties Accrued												$ 314,011				314,011
Short-term Debt, Total												1,464,146				1,464,146
Debt Instrument, Unamortized Discount, Total												0				0
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 2.589
Dr. Schwartz Note, One [Member]
Debt Instrument, Face Amount																				$ 370,000
Debt Instrument, Unamortized Discount, Total																				$ 63,028
Proceeds from Related Party Debt											$ 370,000
DrSchwartz Notes [Member]
Debt Instrument, Face Amount			$ 2,115,000					$ 2,115,000											$ 1,920,000
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Short-term Debt, Total			2,192,878
Interest Payable			$ 77,878
DrSchwartz Notes [Member] | Conversion of Promissory Note Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,583,481
Borrowings Against Equity Line [Member]
Debt Instrument, Face Amount												$ 1,098,684				$ 1,098,684
Debt Instrument, Interest Rate, Stated Percentage												8.00%				8.00%
Proceeds from Short-term Debt, Total																$ 1,020,000
Payments for Penalties																247,327
Short-term Debt, Total												$ 0				0
Repayments of Short-term Debt, Total																1,459,973
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount							$ 2,297,727
Proceeds from Notes Payable, Total							$ 2,000,000
Stock Issued During Period, Shares, New Issues (in shares)							65,000			16,667
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Increase (Decrease), Net, Total										$ 344,659
Debt Conversion, Original Debt, Amount																267,328
Securities Purchase Agreements [Member] | Promissory Note [Member]
Debt Instrument, Face Amount					$ 300,000				$ 847,500
Stock Issued During Period, Shares, New Issues (in shares)									8,857
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Debt Conversion, Original Debt, Amount												$ 525,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)												1,136,448
Proceeds from Short-term Debt, Total									$ 700,000
Stock Issued During Period, Shares, Extension of Notes Payable (in shares)					30,000
Gain (Loss) on Extinguishment of Debt, Total													$ (345,000)	$ (300,000)
Payments for Penalties																0
Penalties Accrued												$ 320,542				320,542
Short-term Debt, Total												1,490,833				1,490,833
Debt Instrument, Unamortized Discount, Total												$ 244,830				$ 244,830
Securities Purchase Agreements [Member] | Promissory Note [Member] | Maturity Extension to March 31, 2021 [Member]
Gain (Loss) on Extinguishment of Debt, Total													(690,000)
Securities Purchase Agreements [Member] | Second Promissory Note [Member]
Gain (Loss) on Extinguishment of Debt, Total													(172,500)
Securities Purchase Agreements [Member] | Second Promissory Note [Member] | Maturity Extension to March 31, 2021 [Member]
Gain (Loss) on Extinguishment of Debt, Total													$ (345,000)
Debt Issued in September 2018, September, 2019, and February 2020 [Member]
Repayments of Debt	$ 5,906,802
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total				$ 541,867

Note 6 - Notes Payable - Notes

Note 6 - Notes Payable - Notes Payable (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Notes Payable, Gross	$ 0	$ 4,676,755
Debt Instrument, Unamortized Discount, Total	0	244,830
Notes Payable	0	4,431,925
Convertible Promissory Note [Member]
Notes Payable, Gross	0	1,721,776
Promissory Note, One [Member]
Notes Payable, Gross	0	1,490,833
Promissory Note, Two [Member]
Notes Payable, Gross	$ 0	$ 1,464,146

Note 7 - Derivatives (Details T

Note 7 - Derivatives (Details Textual)	Sep. 28, 2018	Mar. 31, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Mar. 01, 2021USD ($)	Jun. 30, 2020USD ($)	May 08, 2020USD ($)	Mar. 18, 2020USD ($)	Feb. 05, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total				$ 50,989
Derivative Liability, Total				0
Embedded Derivative, Fair Value of Embedded Derivative Liability			$ 129,480							$ 294,382		$ 50,989
Gain (Loss) on Derivative Instruments, Net, Pretax, Total			164,902	1,765,907
Promissory Note 2020 Conversion Feature, Tranche One [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 68,796
Promissory Note 2020 Conversion Feature, Tranche Two [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									52,125
Promissory Note 2020 Conversion Feature, Tranche Three [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 20,542
Promissory Note 2020 Conversion Feature [Member]
Derivative Liability, Total			104,529	104,529	$ 0
Derivative, Gain (Loss) on Derivative, Net, Total				87,923
A, B and Agent Warrants [Member]
Derivative Liability, Total			41,336	33,654				$ 2,669,995
Derivative, Gain (Loss) on Derivative, Net, Total			(7,683)	69,479
A, B and Agent Warrants, Prior to Reclassification [Member]
Derivative, Gain (Loss) on Derivative, Net, Total		$ 700,910
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative Liability, Total							$ 1,324,184
Embedded Derivative, Fair Value of Embedded Derivative Liability				1,324,184
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				(460,065)
Agent Warrants Issued In connection With May 2020 Offering [Member]
Derivative Liability, Total			33,819	42,646
Derivative, Gain (Loss) on Derivative, Net, Total			(8,827)
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				48,675
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total						$ 1,749,721
Embedded Derivative, Fair Value of Embedded Derivative Liability				1,749,721
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				834,520
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total			45,498	32,701
Derivative, Gain (Loss) on Derivative, Net, Total			12,797
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				79,045
Promissory Note 2019 Conversion Feature [Member]
Derivative Liability, Total											$ 495,100
Promissory Note 2019 Conversion Feature Agent Warrants [Member]
Derivative Liability, Total				89,680	$ 0
Derivative, Gain (Loss) on Derivative, Net, Total			$ 89,680
Gain (Loss) on Derivative Instruments, Net, Pretax, Total				$ 405,420
Bridge Notes [Member] | Convertible Promissory Note [Member]
Debt Instrument, Convertible, Threshold Trading Days	20

Note 7 - Derivatives - Change i

Note 7 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021
Derivative liability balance	$ 294,382	$ 50,989
Derivative instrument recognized for May 2020 Warrants		294,382	$ 129,480
Reclassification of Warrant liabilities to Equity on exercise	(1,701,756)
Reclassification of Warrant liabilities to Equity	(2,669,408)
Gain recognized to revalue derivative instrument at fair value	(164,902)	(1,765,906)
Derivative liability balance		$ 294,382
A, B and Agent Warrants [Member]
Derivative instrument recognized	2,669,995
Promissory Note 2020 [Member]
Derivative instrument recognized	120,921
Warrants and Agent Warrants In Connection With May 2020 Warrant [Member]
Derivative instrument recognized for May 2020 Warrants	1,324,184
Derivative liability balance	1,324,184
Warrants and Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative instrument recognized	495,100
Derivative instrument recognized for May 2020 Warrants	1,749,721
Derivative liability balance	1,749,721
Promissory Note 2020 2 [Member]
Derivative instrument recognized	$ 20,542

Note 8 - Loss Per Share - Share

Note 8 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Net loss attributable to common shareholders per common share: basic and diluted calculation		$ (19,657,174)	$ (26,438,684)
Weighted average common shares outstanding-basic (in shares)	[1]	54,876,044	11,950,154
Effect of diluted stock options, warrants and preferred stock (1) (in shares)		0	0
Weighted average common shares outstanding-diluted (in shares)		54,876,044	11,950,154
Loss per common share-basic and diluted (in dollars per share)		$ (0.36)	$ (2.21)
[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

Note 8 - Loss Per Share - Antid

Note 8 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	1,062,871	1,013,547
Warrant [Member]
Antidilutive Securities (in shares)	31,699,885	7,353,376
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)		1,107,544
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	79,246	79,246

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit), Total	$ (661,658)	$ 0
Valuation Allowance Percentage	100.00%
Unrecognized Tax Benefits, Ending Balance	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	308,990,822	297,735,754
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	259,490,005	261,455,216
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	49,500,817	36,280,538
Operating Loss Carryforwards, Valuation Allowance, Total	62,034,750	59,913,739
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	227,277,399	222,290,524
Operating Loss Carryforwards, Valuation Allowance, Total	$ 23,145,374	22,191,346
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Valuation Allowance, Total		$ 0

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statutory federal income tax benefit	$ 4,266,955	$ 5,434,463
State tax benefit, net of federal taxes	793,282	578,746
Foreign tax benefit	0	62,146
Foreign operations tax rate differential	0	(44,120)
State rate adjustment	5,153	65,112
Nondeductible/nontaxable items	(260,768)	(268,968)
Goodwill impairment	605,420	2,762,014
NOL adjustments	(612,588)	(1,141,662)
Other	150,083	(461,020)
Valuation allowance increase	(3,075,039)	(1,462,683)
Total income tax benefit	$ 661,658	$ 0

Note 9 - Income Taxes - Compone

Note 9 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory	$ 0	$ 7,196
Compensation accruals	58,829	63,846
Accruals and reserves	50,537	162,628
Deferred revenue	26,198	11,641
Charitable contribution carryover	1,095	4,331
Derivatives	27,859	63,145
Intangibles	700,876	295,941
Right of use asset	18,543	13,861
NSQO compensation	1,602,429	1,738,217
NOL and credits	82,814,111	80,038,356
Total deferred tax assets	85,300,477	82,400,860
Depreciation	(120,353)	(295,775)
Total deferred tax liabilities	(120,353)	(295,775)
Net deferred tax assets	85,180,124	82,105,085
Less: valuation allowance	(85,180,124)	(82,105,085)
Total	$ 0	$ 0

Note 10 - Goodwill and Intang_3

Note 10 - Goodwill and Intangibles (Details Textual)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Nov. 24, 2021USD ($)	Dec. 31, 2019USD ($)	Apr. 04, 2019USD ($)
Amortization of Intangible Assets, Total				$ 374,328	$ 313,709
Intangibles, net	$ 3,398,101			3,962,118	3,398,101
Impairment of Intangible Assets (Excluding Goodwill), Total				2,893,548	0
Impairment of Intangible Assets, Software Acquired				1,249,727	0
Goodwill, Ending Balance	2,813,792			6,857,790	2,813,792		$ 15,690,290
Goodwill, Impairment Loss	9,879,498	$ 2,813,792	$ 2,997,000	2,813,792	12,876,498
Goodwill, Impaired, Accumulated Impairment Loss	$ 20,976,498	$ 23,790,290			20,976,498
Helomics Holding Corp. [Member]
Goodwill, Decrease in Growth Rate of 0.5 Percent, Reduction in Fair Value					588,000
Goodwill, Increase in Discount Rate of 0.5 Percent, Reduction in Fair Value					$ 988,000
Measurement Input, Expected Cash Flow Term [Member]
Reporting Unit Measurement Input	10	10	20		10
Measurement Input, Long-term Revenue Growth Rate [Member]
Reporting Unit Measurement Input	0.050	4	0.030		0.050
Measurement Input, Discount Rate [Member]
Reporting Unit Measurement Input	0.140	15	0.25		0.140
Measurement Input, Risk Premium [Member]
Reporting Unit Measurement Input	0.010		0.10		0.010
Helomics Holding Corp. [Member]
Goodwill, Ending Balance								$ 23,790,290
zPREDICTA [Member]
Goodwill, Ending Balance						$ 6,857,790
Goodwill, Acquired During Period				$ 6,857,790

Note 10 - Goodwill and Intang_4

Note 10 - Goodwill and Intangibles - Components of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Amortization	$ (1,102,649)	$ (728,320)
Net Carrying Amount	3,962,118
Impairment, indefinite	2,893,548	0
Total, Gross Carrying Costs	7,958,314	4,126,421
Impairment	2,893,548	0
Total, Net Carrying Amount	3,962,118	3,398,101
Trade Names 1 [Member]
Tradename		398,000
Tradename		(5,452)
Tradename	77,917	392,548
Patents and Trademarks [Member]
Gross Carrying Costs	453,314	401,421
Accumulated Amortization	(230,572)	(211,110)
Impairment, finite	0
Net Carrying Amount	222,742	190,311
Developed Technology Rights [Member]
Gross Carrying Costs	6,382,000	2,882,000
Accumulated Amortization	(432,733)	(252,175)
Impairment, finite	2,485,725
Net Carrying Amount	3,463,542	2,629,825
Customer Relationships [Member]
Gross Carrying Costs	645,000	445,000
Accumulated Amortization	(410,000)	(259,583)
Impairment, finite	37,083
Net Carrying Amount	197,917	$ 185,417
Trade Names [Member]
Tradename	478,000
Tradename	(29,344)
Impairment, indefinite	$ 370,740

Note 10 - Goodwill and Intang_5

Note 10 - Goodwill and Intangibles - Estimated Future Amortization Expense (Details)	Dec. 31, 2021USD ($)
2022	$ 411,609
2023	411,610
2024	411,610
2025	409,526
2026	391,610
Thereafter	1,926,153
Total	$ 3,962,118

Note 10 - Goodwill and Intang_6

Note 10 - Goodwill and Intangibles - Goodwill (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Goodwill		$ 2,813,792	$ 15,690,290	$ 2,813,792	$ 15,690,290
Impairment	$ (9,879,498)	$ (2,813,792)	$ (2,997,000)	(2,813,792)	$ (12,876,498)
zPREDICTA [Member]
Goodwill, Acquired During Period				$ 6,857,790

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual)	12 Months Ended
	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Operating Lease, Expense | $	$ 595,669	$ 565,581
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
Area of Real Estate Property (Square Foot)	5,773
Corporate Office, Minnesota, Used for Office Space [Member]
Area of Real Estate Property (Square Foot)	2,945
Corporate Office, Minnesota, Used for Manufacturing [Member]
Area of Real Estate Property (Square Foot)	2,828
Helomics' Offices [Member]
Lessee, Operating Lease, Term of Contract (Year)	3 years
Area of Real Estate Property (Square Foot)	17,417
Helomics Offices, Lease Area for Office Space [Member]
Area of Real Estate Property (Square Foot)	1,000
Helomics Offices, Lease Area for Laboratory [Member]
Area of Real Estate Property (Square Foot)	16,417
zPREDICTA Offices in San Jose California [Member]
Area of Real Estate Property (Square Foot)	1,236
Soluble Biodtech Offices in Birmingham, Alabama [Member]
Area of Real Estate Property (Square Foot)	4,314
TumorGenesis Offices In Salem Massachusetts [Member]
Area of Real Estate Property (Square Foot)	1,450
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property (Square Foot)	2,000
Skyline Medical Europe's Offices Lease, Storage Space [Member]
Area of Real Estate Property (Square Foot)	750
Skyline Medical Europe's Offices Lease, Office Space [Member]
Area of Real Estate Property (Square Foot)	1,250

Note 11 - Leases - Lease Inform

Note 11 - Leases - Lease Information (Details)	Dec. 31, 2021	Dec. 31, 2020
Weighted average remaining lease term – operating leases in years (Year)	1 year 8 months 8 days	2 years 3 months 29 days
Weighted average discount rate – operating leases	8.00%	8.00%

Note 11 - Leases - Rent Obligat

Note 11 - Leases - Rent Obligation (Details)	Dec. 31, 2021USD ($)
2022	$ 751,345
2023	188,931
2024	71,420
2025	48,552
Total lease payments	1,060,248
Less interest	180,922
Present value of lease liabilities	$ 879,326

Note 12 - Property, Plant and_3

Note 12 - Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 2,893,548	$ 0
Impairment of Intangible Assets, Software Acquired	1,249,727	0
Depreciation, Total	965,973	$ 711,139
Other Finite-lived Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	$ 0

Note 12 - Property, Plant and_4

Note 12 - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant, and Equipment Gross	$ 4,579,909	$ 5,154,547
Less: Accumulated depreciation	2,068,338	1,331,847
Total fixed assets, net	2,511,571	3,822,700
Office Equipment [Member]
Property, Plant, and Equipment Gross	517,488	1,862,669
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,456,091	2,811,011
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	428,596	315,297
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	121,120	108,956
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 56,614	$ 56,614

Note 13 - Segments (Details Tex

Note 13 - Segments (Details Textual)	12 Months Ended
	Dec. 31, 2021
Number of Operating Segments	4

Note 13 - Segments - Segments (

Note 13 - Segments - Segments (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Revenue				$ 1,420,680	$ 1,252,272
Depreciation and Amortization				(1,340,301)	(1,024,848)
Impairment	$ (9,879,498)	$ (2,813,792)	$ (2,997,000)	(2,813,792)	(12,876,498)
Impairment expense – intangibles				(2,893,548)	0
Impairment expense – acquired software				(1,249,727)	0
Net loss				(19,657,174)	(25,884,397)
Assets	13,060,436			43,771,271	13,060,436
Impairment expense					(12,876,498)
Net loss				(19,657,174)	(25,884,397)
Corporate, Non-Segment [Member]
Revenue				4,119	0
Depreciation and Amortization				(16,319)	(41,362)
Net loss				(7,089,286)	(8,968,648)
Assets	211,510			28,536,489	211,510
Impairment expense					0
Net loss				(7,089,286)	(8,968,648)
Skyline [Member] | Operating Segments [Member]
Revenue				1,169,811	1,185,214
Depreciation and Amortization				(30,002)	(38,310)
Net loss				(520,822)	(1,132,251)
Assets	1,191,439			906,977	1,191,439
Impairment expense					0
Net loss				(520,822)	(1,132,251)
Helomics Segment [Member] | Operating Segments [Member]
Revenue				13,367	64,188
Depreciation and Amortization				(886,642)	(761,105)
Impairment				(2,813,792)
Impairment expense – intangibles				(2,893,548)
Impairment expense – acquired software				(1,249,727)
Net loss				(11,326,948)	(15,112,131)
Assets	9,773,902			1,802,792	9,773,902
Impairment expense					(12,876,498)
Net loss				(11,326,948)	(15,112,131)
Soluble [Member] | Operating Segments [Member]
Revenue				233,293	2,870
Depreciation and Amortization				(366,713)	(184,071)
Net loss				(1,251,564)	(671,367)
Assets	$ 1,883,585			1,742,445	1,883,585
Impairment expense					0
Net loss				(1,251,564)	$ (671,367)
zPREDICTA [Member] | Operating Segments [Member]
Revenue				90
Depreciation and Amortization				(40,625)
Net loss				531,446
Assets				10,782,568
Net loss				$ 531,446

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - USD ($)	May 01, 2019	Apr. 01, 2019
Director [Member]
Related Party Transaction, Monthly Cash Payment	$ 13,500	$ 12,000

Note 15 - Retirement Savings _2

Note 15 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 127,953	$ 119,555
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - Equity Line Purchase Agreement [Member] - USD ($)	Oct. 24, 2019	Mar. 28, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Issued During Period, Shares, New Issues (in shares)	104,651		647,504	4,231,073
Stock Issued During Period, Value, New Issues	$ 450,000		$ 675,590	$ 4,891,348
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		120,000
Stock Issued During Period, Value, New Issues		$ 86,885